Michel Dahan

Michel Dahan

Former Senior Vice President, Chief Operating OfficeratAkebia Therapeutics· In proxies 2021–2024

Pay in FY2024-3% from the year before · Akebia Therapeutics stock +53.2% the same year

Michel Dahan was paid $1.2M in FY2024 (Dec), down 3%. Akebia Therapeutics stock rose 53.2% that year.

Pay$100 in the stock at the end of FY20 → $68
Pay is from the Summary Compensation Table of each Akebia Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Akebia TherapeuticsPublic company · 5 yr
    • Former Senior Vice President, Chief Operating Officer2021 – Present · 5 yrStock in role -74%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?